The 7 major ringworm markets are expected to exhibit a CAGR of 3.49% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2034
|
Historical Years
|
2018-2023
|
Market Growth Rate 2024-2034 | 3.49% |
The ringworm market has been comprehensively analyzed in IMARC's new report titled "Ringworm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ringworm, also known as dermatophytosis or tinea corporis, is a common fungal infection that affects various parts of the body, including the scalp, groin area, feet, and nails. It is highly contagious and can be transmitted through direct contact with an infected person, animals, or contaminated objects (such as towels, clothing, surfaces, etc.). This ailment manifests as a circular or ring-shaped rash with red edges and healthy-looking skin in the center. The affected area may be itchy or scaly and can develop small blisters or pustules. In cases of nail ringworm, the nails commonly become thickened, brittle, or discolored and may form white or yellow patches. The diagnosis of the illness is typically made based on clinical investigation, medical history, and visual examination. A fungal culture is also recommended to confirm the diagnosis and identify the specific species causing the infection. The healthcare provider may further conduct a skin scraping test using a scalpel blade or the blunt edge of a glass slide to check for the presence of fungal elements, such as hyphae or spores, among patients.
The increasing cases of direct contact with contaminated surfaces that can enhance the transfer of fungal spores and lead to infection are primarily driving the ringworm market. In addition to this, the rising prevalence of various associated risk factors, including lack of proper hygiene practices, warm and humid environments, compromised immune systems, living in crowded spaces, excessive sweating, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of polymerase chain reaction techniques to detect the genetic material (DNA) of the fungus causing the infection is further bolstering the market growth. This test can provide rapid and accurate results, especially when other diagnostic methods are inconclusive. Apart from this, the inflating application of antifungal drugs, such as terbinafine, fluconazole, itraconazole, etc., since they work by disrupting the synthesis of ergosterol in the fungal cell membrane, preventing the spread of the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intravenous griseofulvin therapy to treat severe disease conditions owing to its several benefits, like enhanced absorption, a quicker onset of action, and improved compliance, is expected to drive the ringworm market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the ringworm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ringworm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ringworm market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current ringworm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Naftin gel (Naftifine topical) | Sebela Pharmaceuticals |
Lamisil (Terbinafine) | Novartis |
Mentax (Butenafine) | Kaken Pharmaceutical |
Luzu (Luliconazole) | |
DBI001 | DermBiont |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Ringworm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies